18F-FDG PET response to neoadjuvant chemotherapy for Ewing sarcoma and osteosarcoma are different.
about
Management of Ewing sarcoma family of tumors: Current scenario and unmet needPerformance of Positron Emission Tomography and Positron Emission Tomography/Computed Tomography Using Fluorine-18-Fluorodeoxyglucose for the Diagnosis, Staging, and Recurrence Assessment of Bone Sarcoma: A Systematic Review and Meta-Analysis.Applying Advanced Imaging Techniques to a Murine Model of Orthotopic Osteosarcoma.Prognostic Value of SUVmax Measured by Pretreatment Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Patients with Ewing Sarcoma.The Role of Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Assessing the Response to Neoadjuvant Treatment in Patients with Osteosarcoma.A Novel System for the Surgical Staging of Primary High-grade Osteosarcoma: The Birmingham Classification.Prognostic relevance of ¹⁸F-FDG PET uptake in patients with locally advanced, extremity soft tissue sarcomas undergoing neoadjuvant isolated limb perfusion with TNF-α and melphalan.Response to chemotherapy estimates by FDG PET is an important prognostic factor in patients with Ewing sarcoma.Prognostic value of FDG-PET indices for the assessment of histological response to neoadjuvant chemotherapy and outcome in pediatric patients with Ewing sarcoma and osteosarcoma.18F-FDG PET/CT as an Indicator of Survival in Ewing Sarcoma of Bone.Atypical growth on MRI in a case of Ewing's sarcoma despite lower SUV on PET.Initial FDG-PET/CT predicts survival in adults Ewing sarcoma family of tumors.[Postoperative and posttherapeutic changes after primary bone tumors : What's important for radiologists?]Correlation between equivalent cross-relaxation rate and cellular density in soft tissue tumors.
P2860
Q28073218-99FFB9B9-26FC-424D-87BF-D1BF7D481F71Q35769381-3D4CC6BE-0110-4692-84A1-8B0F7003EB4DQ35910674-7C960137-F7A0-4BA3-84B3-5E0FE411F23BQ35995816-1B4B0F54-9238-40E2-860D-C5DF41C8417BQ38046209-31AC94AC-642A-4522-AB6F-45D5A41A0054Q38823680-C9B87FB1-57ED-43D2-A6C2-B7B20FB6F05CQ39251874-CDC7310F-FDC0-4E1A-8047-DD951D257B3AQ40650204-0DB54F72-9007-4479-98FD-8A848E3E7049Q41523153-309B694F-F76C-4AB9-85F7-949A97F93E12Q41721716-8144E1BB-AEA5-4799-B9BF-B40C1A184927Q45296597-505FF4BC-B763-4AA3-A102-00392B60C0EAQ47119469-A19EF4EA-C7B5-4AD1-A242-EAF832AA6110Q49546357-759776BC-919D-43F1-941D-3DE140E4B799Q51140255-98D35EBA-56C4-4374-B3B5-4E400F896B76
P2860
18F-FDG PET response to neoadjuvant chemotherapy for Ewing sarcoma and osteosarcoma are different.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
18F-FDG PET response to neoadj ...... nd osteosarcoma are different.
@en
18F-FDG PET response to neoadj ...... nd osteosarcoma are different.
@nl
type
label
18F-FDG PET response to neoadj ...... nd osteosarcoma are different.
@en
18F-FDG PET response to neoadj ...... nd osteosarcoma are different.
@nl
prefLabel
18F-FDG PET response to neoadj ...... nd osteosarcoma are different.
@en
18F-FDG PET response to neoadj ...... nd osteosarcoma are different.
@nl
P2093
P2860
P50
P1433
P1476
18F-FDG PET response to neoadj ...... and osteosarcoma are different
@en
P2093
Claudia Di Bella
John Slavin
Louie L Gaston
P2860
P2888
P304
P356
10.1007/S00256-011-1096-4
P577
2011-02-06T00:00:00Z